Overview
- The board approved the company‑wide plan on July 21, which Boston Scientific laid out in a July 27 regulatory filing with cost and timing estimates.
- Management estimates $700 million to $800 million in pre‑tax charges with $600 million to $700 million in cash outlays and about $500 million in annual expense savings when fully implemented.
- The program will optimize supply chains, shift some production between factories, and reorganize operations as changes begin in 2026 and run through the end of 2029.
- Boston Scientific said the plan will include some job cuts while it continues hiring in higher‑growth areas and reallocates resources to meet global demand.
- Investors are focused on second‑quarter results due July 29 and the company’s heart‑device performance because near‑term revenue growth is slowing and market reaction can affect stock momentum.